Medtronic (NYSE:MDT) Given New $90.00 Price Target at UBS Group

Medtronic (NYSE:MDT) had its price target cut by UBS Group from $104.00 to $90.00 in a report released on Wednesday,Benzinga reports. They currently have a neutral rating on the medical technology company’s stock.

MDT has been the subject of several other research reports. Wells Fargo & Company began coverage on shares of Medtronic in a research note on Friday, January 30th. They set an “overweight” rating and a $114.00 price objective for the company. Mizuho reduced their price objective on shares of Medtronic from $125.00 to $120.00 and set an “outperform” rating for the company in a research note on Monday, April 13th. Argus reduced their price objective on shares of Medtronic from $125.00 to $115.00 and set a “buy” rating for the company in a research note on Monday, April 6th. Stifel Nicolaus reduced their price objective on shares of Medtronic from $105.00 to $95.00 and set a “hold” rating for the company in a research note on Monday, April 6th. Finally, Barclays boosted their price target on shares of Medtronic from $118.00 to $120.00 and gave the stock an “overweight” rating in a research note on Wednesday, April 1st. Fifteen analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $108.55.

Medtronic Price Performance

Shares of NYSE:MDT opened at $83.23 on Wednesday. The company has a 50 day moving average of $90.44 and a 200 day moving average of $95.44. The stock has a market cap of $106.86 billion, a P/E ratio of 23.18, a P/E/G ratio of 2.13 and a beta of 0.75. Medtronic has a 12 month low of $79.93 and a 12 month high of $106.33. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 EPS for the quarter, beating the consensus estimate of $1.34 by $0.02. The company had revenue of $9.02 billion during the quarter, compared to analysts’ expectations of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. Medtronic’s revenue for the quarter was up 5.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.38 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, sell-side analysts forecast that Medtronic will post 5.57 EPS for the current fiscal year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were paid a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date of this dividend was Friday, March 27th. Medtronic’s payout ratio is currently 79.11%.

Insider Buying and Selling

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the transaction, the executive vice president owned 32,768 shares of the company’s stock, valued at $3,201,761.28. The trade was a 61.58% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.26% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Medtronic

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Corundum Trust Company INC purchased a new stake in shares of Medtronic in the 3rd quarter valued at $27,000. Lodestone Wealth Management LLC purchased a new stake in shares of Medtronic in the 4th quarter valued at $27,000. Anfield Capital Management LLC boosted its stake in shares of Medtronic by 410.7% in the 4th quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 230 shares in the last quarter. Monetary Solutions Ltd purchased a new stake in shares of Medtronic in the 4th quarter valued at $27,000. Finally, Valley Wealth Managers Inc. purchased a new stake in shares of Medtronic in the 3rd quarter valued at $29,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: CathWorks acquisition closed and AI coronary diagnostics bolstering Medtronic’s cardiovascular software/hardware stack — expands addressable market and recurring‑revenue potential. Medtronic Expands AI Heart Care As Investors Weigh Valuation And Momentum
• Positive Sentiment: Led a $100M investment in Pulnovo plus a commercial agreement to broaden therapies/commercialisation for cardio and hypertension treatments — shows active dealmaking to extend product pipeline and global reach. Medtronic leads $100M investment in Pulnovo Medical
• Positive Sentiment: New product momentum — Altaviva™ implant publicity (Edison Award) and first clinical use of the Stealth AXiS Autopilot robotic platform signal commercialization progress and potential future device sales. Medtronic (MDT) Valuation Check As New GE HealthCare Tie Up And Altaviva Launch Draw Investor Interest First surgeons use Medtronic Stealth AXiS Autopilot surgical robotic platform
• Neutral Sentiment: Company says CathWorks deal will be immaterial to FY2027 earnings and neutral-to-accretive in later years — suggests benefits are longer‑term rather than immediate. Medtronic concludes CathWorks’ acquisition for $585m
• Neutral Sentiment: Industry reports (wearable injectors market) cite Medtronic among players in growing home‑health/wearables opportunity — supportive for long-term addressable market but not an immediate revenue catalyst. Wearable Injectors Market Report 2026
• Negative Sentiment: UBS cut its price target from $104 to $90 and set a neutral rating — analyst downgrade and lower target add near‑term selling pressure and feed valuation worries. UBS lowers Medtronic price target
• Negative Sentiment: Recent coverage highlights share‑price weakness and YTD declines, reflecting investor concern over momentum and valuation despite product/AI catalysts. Is It Time To Reconsider Medtronic (MDT) After Recent Share Price Weakness?

About Medtronic

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).